Skip to main content

Together we are beating cancer

Donate now

Showing 12 out of 15 results
Seb
  • Science & Technology
  • For Researchers

Embracing a full spectrum of researchers

For drug discovery scientist Sebastian Greenhough, a late diagnosis of autism made sense of several things – but something it certainly didn’t do was stand in the way of his research For drug discovery scientist Sebastian Greenhough, a late diagnosis of autism made sense of several things – but something it certainly didn’t do was stand in the way of his research

by Cancer Research UK | Analysis | 24 February 2022

24 February 2022

This entry is part 5 of 10 in the series Diversity in research
Breast cancer exam.

Research finds women with breast pain alone were no more to receive a diagnosis of breast cancer than women with no symptoms. Research finds women with breast pain alone were no more to receive a diagnosis of breast cancer than women with no symptoms.

by Lilly Matson | News | 22 February 2022

22 February 2022

Illustration showing inequalities.

We talk to Professor Sir Michael Marmot, who's been at the forefront of health inequality research for decades, to discuss what it is and how we can reduce it. We talk to Professor Sir Michael Marmot, who's been at the forefront of health inequality research for decades, to discuss what it is and how we can reduce it.

by Harry Jenkins | Analysis | 15 February 2022

15 February 2022

This entry is part 1 of 5 in the series Health inequalities
Photograph of a person having an MRI scan.

New research has found that using an advanced MRI technique may enable doctors to pinpoint potentially aggressive or fast-growing cancers and guide treatment pathways. New research has found that using an advanced MRI technique may enable doctors to pinpoint potentially aggressive or fast-growing cancers and guide treatment pathways.

by Lilly Matson | Analysis | 14 February 2022

14 February 2022

Vivian Li, group leader of the stem cell and cancer biology lab at the Francis Crick Institute

Disrupted cell signalling, hijacked stem cells and the power of 'mini-guts' – we hear from Dr Vivian Li on the challenges and opportunities of developing colorectal cancer treatments. Disrupted cell signalling, hijacked stem cells and the power of 'mini-guts' – we hear from Dr Vivian Li on the challenges and opportunities of developing colorectal cancer treatments.

by Phil Prime | In depth | 11 February 2022

11 February 2022

Breast cancer tissue under the microscope.

A study by Oxford University has found that aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in both younger and older women. A study by Oxford University has found that aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in both younger and older women.

by In collaboration with PA Media Group | News | 11 February 2022

11 February 2022

A photograph of a lab at the Imperial Cancer Research Fund in the 1960's.
  • Science & Technology
  • Health & Medicine

Diving into our role in 50 top cancer drugs

To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities' that led to many of the drugs in use today. To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities' that led to many of the drugs in use today.

by Catherine Pickworth | In depth | 9 February 2022

9 February 2022

Michelle Mitchell chief executive Cancer Research UK
  • Health & Medicine
  • Policy & Insight

Javid's war on cancer can't leave people behind

We’ve had plans before. What we need is leadership, commitment and competence. Addressing cancer inequalities and cancer prevention must be central to the plan. We’ve had plans before. What we need is leadership, commitment and competence. Addressing cancer inequalities and cancer prevention must be central to the plan.

by Michelle Mitchell | Opinion | 4 February 2022

4 February 2022

The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life. The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life.

by Phil Prime | Podcast | 4 February 2022

4 February 2022

This entry is part 1 of 9 in the series Cancer Research Matters - series 1

Chief clinician Charlie Swanton gives some of his personal reflections on how far research has come and why sustained investment is so important for the therapies of the future. Chief clinician Charlie Swanton gives some of his personal reflections on how far research has come and why sustained investment is so important for the therapies of the future.

by Charles Swanton | Analysis | 4 February 2022

4 February 2022